Custom Search Insider Trading Activity Insider Trading Activity
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Custom Search Insider Trading Activity
Updated Sep 17, 2024
Ticker
|
Company Name
|
Qty.
|
Price
|
Size ($)
|
Filing Date
|
Type
|
Δ Own
|
Own
|
Insider Names
|
Title
|
Trade Dates
|
Is Scheduled
| |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioxcel Therapeutics, Inc.
| 535 |
$0.69 | -$148.52 | +15.29% | 4.03K |
Sep 15 - Sep 16
|
Scheduled
| ||||||
Bioxcel Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
Jun 15
| |||||||
Bioxcel Therapeutics, Inc.
| 506 |
$1.26 | -$308.10 | +16.91% | 3.5K |
Jun 15 - Jun 17
|
Scheduled
| ||||||
Bioxcel Therapeutics, Inc.
| 1.99K |
$2.64 | -$2,656.18 | +49.80% | 5.99K |
Mar 15 - Apr 4
|
Scheduled
| ||||||
Bioxcel Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
Mar 15
| |||||||
Bioxcel Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
|
Jan 17
| |||||||
Bioxcel Therapeutics, Inc.
|
0
|
—
|
—
|
—
|
0
| ||||||||
Menlo Therapeutics Inc.
|
0
|
—
|
—
|
—
|
0
| ||||||||
Foamix Pharmaceuticals Ltd.
| -114.07K |
—
|
—
| -100.00% |
0
|
Mar 9
| |||||||
Foamix Pharmaceuticals Ltd.
| 1.99K |
$2.68 | $5,336.26 | +1.78% | 114.07K |
Mar 2
| |||||||
Foamix Pharmaceuticals Ltd.
| 41.3K |
—
|
—
| +58.35% | 112.08K |
Feb 24
| |||||||
Foamix Pharmaceuticals Ltd.
| -2.50K |
$3.28 | -$8,200.00 | -3.41% | 70.78K |
Dec 31
| |||||||
Foamix Pharmaceuticals Ltd.
| 9.84K |
$2.16 | $21,248.88 | +15.51% | 73.28K |
Nov 29
| |||||||
Foamix Pharmaceuticals Ltd.
| 13.44K |
$3.76 | $50,534.40 | +26.88% | 63.44K |
Mar 5
| |||||||
Foamix Pharmaceuticals Ltd.
| 50K |
—
|
—
|
∞
| 50K |
Dec 3
| |||||||
Foamix Pharmaceuticals Ltd.
|
0
|
—
|
—
|
—
|
0
| ||||||||
It looks like there's no data for these filter options. Maybe you'll be interested in these options instead. | |||||||||||||